Amzeeq 4% Topical Foam — Competitive Intelligence Brief

Amzeeq 4% Topical Foam (Amzeeq 4% Topical Foam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Dermatology.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit; matrix metalloproteinases Dermatology Small molecule

Target snapshot

Amzeeq 4% Topical Foam (Amzeeq 4% Topical Foam) — Edward Lain, MD. Amzeeq is a topical foam formulation of minocycline that reduces inflammation and bacterial colonization in acne by inhibiting bacterial protein synthesis and suppressing inflammatory mediators.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amzeeq 4% Topical Foam TARGET	Amzeeq 4% Topical Foam	Edward Lain, MD	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit; matrix metalloproteinases
Vibramycin	doxycycline	Generic (originally Pfizer)	marketed	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Doxycycline (Oracea)	Doxycycline (Oracea)	LEO Pharma	marketed	Tetracycline antibiotic (anti-inflammatory formulation)	Matrix metalloproteinases (MMPs); 30S ribosomal subunit
Tetracyclin ointment	Tetracyclin ointment	University of Oslo	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Usual doses of tigecycline	Usual doses of tigecycline	Air Force Specialized Hospital, Cairo, Egypt	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline pre-operatively	Doxycycline pre-operatively	University of Pittsburgh	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Vonoprazan+amoxicillin+tetracycline 14 days	Vonoprazan+amoxicillin+tetracycline 14 days	Xijing Hospital of Digestive Diseases	marketed	Combination therapy: potassium-competitive acid blocker + beta-lactam antibiotic + tetracycline antibiotic	H+ K+-ATPase (vonoprazan); bacterial cell wall (amoxicillin); bacterial ribosome (tetracycline)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2027-12-19 — Vibramycin · 7749532 · Formulation · US

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class